Andreas Hochhaus

New England Journal of Medicine · 2002–2022

A researcher in the Science corpus: 26 papers; trusts 0 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Whom Andreas Hochhaus trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Brian J. Druker
2. M. Baccarani

Who trusts Andreas Hochhaus overall

1. Brian J. Druker
2. M. Baccarani

Papers from Andreas Hochhaus's perspective

Ordered by how strongly the researchers Andreas Hochhaus trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Journal of Clinical Oncology)
2. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (Cancer Cell)
3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. (The Lancet Oncology)
4. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (Journal of Clinical Oncology)
5. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Blood)
6. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
7. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (Blood)
8. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase… (Blood)
9. Updated clinical classification of pulmonary hypertension. (Journal of the American College of Cardiology)
10. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. (Science)

Their papers

• Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders (2010) — 1,197 citations
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022) — 3,276 citations
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022) — 3,492 citations
• Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017) — 1,052 citations
• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016) — 852 citations
• Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. (2013) — 1,750 citations
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) — 1,917 citations
• Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). (2012) — 612 citations
• Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. (2010) — 722 citations
• Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. (2010) — 1,525 citations
• International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (2009) — 672 citations
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) — 1,280 citations
• Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007) — 644 citations
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007) — 616 citations
• Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. (2007) — 765 citations
• Chronic myeloid leukaemia. (2007) — 792 citations
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. (2006) — 1,311 citations
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) — 1,349 citations
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) — 3,470 citations
• Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. (2005) — 932 citations